Efficacy of probiotics for the management of inflammatory bowel disease

Gastroenterology and Hepatology

Volumn 7, Issue 9, 2011, Pages 606-608

  Sartor, R Balfour ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; PROBIOTIC AGENT; SHORT CHAIN FATTY ACID;

ANTIBIOTIC THERAPY; BLOATING; DRUG EFFICACY; DRUG SAFETY; ENTERITIS; HUMAN; ILEITIS; MEDICAL RESEARCH; MICROFLORA; NOTE; RISK ASSESSMENT; TREATMENT OUTCOME;

EID: 81855193743     PISSN: 15547914     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Note

References (6)

1. Sartor RB. Microbial influences in inflammatory bowel diseases. Gastroenterology. 2008;134:577-594. (Pubitemid 351173057)
2. Gionchetti P, Rizzello F, Venturi A, et al. Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: a double-blind, placebo-controlled trial. Gastroenterology. 2000;119:305-309. (Pubitemid 30621980)
3. Kruis W, Fric P, Pokrotnieks J, et al. Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine. Gut. 2004;53:1617-1623. (Pubitemid 39434105)
4. Sokol H, Pigneur B, Watterlot L, et al. Faecalibacterium prausnitzii is an antiinflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients. Proc Natl Acad Sci U S A. 2008;105:16731-16736.
5. Reid G, Gaudier E, Guarner F, et al. Responders and non-responders to probiotic interventions: how can we improve the odds? Gut Microbes. 2010;1:200-204.
6. Cain AM, Karpa KD. Clinical utility of probiotics in inflammatory bowel disease. Altern Ther Health Med. 2011;17:72-79.